Tumor Profiling May Help Identify Inherited Cancer Risk
Tumor analysis can accurately flag specific genetic variants, potentially guiding further testing for patients and their families.
Updated on Oct. 16, 2026 in Cancer
Live Poll
Should medical systems automatically initiate risk screening for relatives of patients with identified genetic cancer markers?
Tumor analysis can accurately identify carriers of certain Israeli founder pathogenic variants, according to a new comparative study. This testing approach may eventually assist in screening patients and their relatives for hereditary cancer risk.
Why it matters
Repurposing existing tumor testing for these specific variants could streamline the identification of individuals with hereditary cancer predispositions. This provides an efficient way to flag patients for germline testing and potential cascade screening for at-risk family members.
A comparative analysis of tumor mutational profiling found 99% concordance between somatic and germline results in a 69-patient cohort. While this study confirms the ability to detect 53 known Israeli founder variants across 12 genes, it remains unclear how this impacts clinical outcomes.
The details
Researchers compared somatic mutation profiling results from 2,769 Israeli tumor samples and 674,849 United States samples to track the presence of 53 specific founder pathogenic variants. By detecting these mutations within tumor tissue, clinicians can identify patients who likely carry the same variants in their germline cells. This approach bypasses the need for initial germline testing in some cases, offering a high-accuracy bridge to further genetic evaluation.
Timeline
October 16, 2026: The study findings were published.
Health Landscape
This development marks a shift in how genetic predispositions are identified, moving beyond primary germline screening to leverage secondary data from tumor profiling. It evolves the diagnostic yield of 2% standard testing by repurposing widespread oncological mutational data.
Patients undergoing tumor profiling for cancer treatment may find that these tests incidentally reveal information about hereditary risk. Discuss the implications of any identified genetic variants with a physician or genetic counselor to determine if cascade screening is needed for relatives.
The takeaway
Tumor analysis can serve as a highly accurate proxy for identifying hereditary genetic variants in certain populations. If you have a family history of cancer, ask your oncologist about the potential for germline testing and whether tumor profiling might provide additional insights into your risk.
Further reading
Learn more about the latest innovations in genetic testing and diagnostics on our Cancer page.
Source note: This article includes information reported by Nature.
Live Poll
Should medical systems automatically initiate risk screening for relatives of patients with identified genetic cancer markers?
